Effects on chlorophyll and carotenoid contents in different grape varieties (Vitis vinifera L.) after nitrogen and elicitor foliar applications to the vineyard

Photosynthetic pigments, including carotenoids are important secondary metabolites, which play a key role in photosynthesis. There is little information about the effects of nitrogen and elicitor applications on chlorophyll and carotenoid concentrations in grapes. The aim of this work was therefore to study the effects of the foliar application of nitrogen sources and elicitors to Tempranillo, Garnacha and Graciano (Vitis vinifera L.) grapevines on chlorophyll and carotenoid contents. The results showed that β-carotene and lutein were the most abundant carotenoids in all the samples, ranging from 1336 and 227 to 7054 and 1382 μg/g, respectively. The applied treatments had greater impact on chlorophyll and carotenoid contents in Tempranillo grapes than in Graciano and Garnacha varieties. The content of chlorophyll was determined by the variety factor, while the concentration of carotenoids was influenced by the interaction of variety and treatment factors, depending on the type of foliar application.EEA MendozaFil: Gutiérrez Gamboa, Gastón. Instituto de Ciencias de la Vid y del Vino. Grupo VIENAP; EspañaFil: Marín San Román, S. Instituto de Ciencias de la Vid y del Vino. Grupo VIENAP; EspañaFil: Jofre, Viviana Patricia. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Mendoza; ArgentinaFil: Rubio Bretón, Pilar. Instituto de Ciencias de la Vid y del Vino. Grupo VIENAP; EspañaFil: Pérez Alvarez, Eva Pilar. Instituto de Ciencias de la Vid y del Vino. Grupo VIENAP; EspañaFil: Garde Cerdán, Teresa. Instituto de Ciencias de la Vid y del Vino. Grupo VIENAP; Españ

La economía solidaria en México.

Investigación sobre las organizaciones colectivas de trabajo e ingreso de México, basadas en la reciprocidad y consideradas parte de la economía solidaria. Se atrae la atención sobre la necesidad de una discusión teórico-metodológica de las propuestas alrededor de estas organizaciones, se presenta además, un conjunto de estudios de caso para saber si las iniciativas colectivas contribuyen a resolver las necesidades materiales de sus integrantes, a la par que se analiza si es posible que se perfilen como embriones de una sociedad anticapitalista, al introducir en sus prácticas cambios de las relaciones sociales; por ejemplo, reciprocidad, igualdad, comunidad, autoridad colectiva y sustentabilidad, en lugar de explotación, dominación, discriminación, deterioro y agotamiento ambiental. Por último, se evalúan las posibilidades de que se constituyan en sujetos colectivos que apunten no solo a otra economía, sino a una sociedad alternativa

Prevalencia de sobrepeso y obesidad en Aragón y variaciones según condicionantes de salud

Introducción: La obesidad infantil constituye un grave problema de salud global en continuo aumento en todo el mundo. Muchos estudios señalan que determinados factores socioeconómicos están relacionados con el desarrollo de obesidad. El objetivo de este estudio fue analizar la prevalencia de sobrepeso y obesidad en Aragón, calculadas según los estándares de la Organización Mundial de la Salud (OMS) y estudiar su relación con factores socioeconómicos. Material y métodos: Se recopiló información sobre la totalidad de la población infantil de Aragón entre dos y 14 años y cada individuo fue clasificado como normopeso, sobrepeso u obesidad según su índice de masa corporal (IMC). Se obtuvieron las prevalencias por provincias y zonas básicas de salud (ZBS). Utilizamos el índice de privación (IP) de Aragón como marcador de la situación socioeconómica. Resultados: La muestra final estuvo constituida por 161.335 niños (51%) y niñas (49%) de dos a 14 años. La prevalencia global de sobrecarga ponderal (SP) fue de 31,1% (17,7% sobrepeso y 13,3% obesidad), siendo significativamente mayor en niños. Detectamos un porcentaje elevado (65%) de infrarregistro en la historia clínica. Se encontró una relación directa entre el IP y la prevalencia de obesidad y SP en todo Aragón, con una fuerte correlación significativa en zonas urbanas, en las que los factores socioeconómicos llegan a explicar hasta 66,4% de la obesidad y 48,9% de la SP tota

INRISCO: INcident monitoRing in Smart COmmunities

Major advances in information and communication technologies (ICTs) make citizens to be considered as sensors in motion. Carrying their mobile devices, moving in their connected vehicles or actively participating in social networks, citizens provide a wealth of information that, after properly processing, can support numerous applications for the benefit of the community. In the context of smart communities, the INRISCO [1] proposal intends for (i) the early detection of abnormal situations in cities (i.e., incidents), (ii) the analysis of whether, according to their impact, those incidents are really adverse for the community; and (iii) the automatic actuation by dissemination of appropriate information to citizens and authorities. Thus, INRISCO will identify and report on incidents in traffic (jam, accident) or public infrastructure (e.g., works, street cut), the occurrence of specific events that affect other citizens' life (e.g., demonstrations, concerts), or environmental problems (e.g., pollution, bad weather). It is of particular interest to this proposal the identification of incidents with a social and economic impact, which affects the quality of life of citizens.This work was supported in part by the Spanish Government through the projects INRISCO under Grant TEC2014-54335-C4-1-R, Grant TEC2014-54335-C4-2-R, Grant TEC2014-54335-C4-3-R, and Grant TEC2014-54335-C4-4-R, in part by the MAGOS under Grant TEC2017-84197-C4-1-R, Grant TEC2017-84197-C4-2-R, and Grant TEC2017-84197-C4-3-R, in part by the European Regional Development Fund (ERDF), and in part by the Galician Regional Government under agreement for funding the Atlantic Research Center for Information and Communication Technologies (AtlantTIC)

Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn’s Disease Patients: The SUSTAIN Study

Background Large real-world-evidence studies are required to confirm the durability of response, effectiveness, and safety of ustekinumab in Crohn’s disease (CD) patients in real-world clinical practice. Methods A retrospective, multicentre study was conducted in Spain in patients with active CD who had received ≥1 intravenous dose of ustekinumab for ≥6 months. Primary outcome was ustekinumab retention rate; secondary outcomes were to identify predictive factors for drug retention, short-term remission (week 16), loss of response and predictive factors for short-term efficacy and loss of response, and ustekinumab safety. Results A total of 463 patients were included. Mean baseline Harvey-Bradshaw Index was 8.4. A total of 447 (96.5%) patients had received prior biologic therapy, 141 (30.5%) of whom had received ≥3 agents. In addition, 35.2% received concomitant immunosuppressants, and 47.1% had ≥1 abdominal surgery. At week 16, 56% had remission, 70% had response, and 26.1% required dose escalation or intensification; of these, 24.8% did not subsequently reduce dose. After a median follow-up of 15 months, 356 (77%) patients continued treatment. The incidence rate of ustekinumab discontinuation was 18% per patient-year of follow-up. Previous intestinal surgery and concomitant steroid treatment were associated with higher risk of ustekinumab discontinuation, while a maintenance schedule every 12 weeks had a lower risk; neither concomitant immunosuppressants nor the number of previous biologics were associated with ustekinumab discontinuation risk. Fifty adverse events were reported in 39 (8.4%) patients; 4 of them were severe (2 infections, 1 malignancy, and 1 fever). Conclusions Ustekinumab is effective and safe as short- and long-term treatment in a refractory cohort of CD patients in real-world clinical practice

Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab

Ustekinumab has shown efficacy in Crohn's Disease (CD) patients. To identify patient profiles of those who benefit the most from this treatment would help to position this drug in the therapeutic paradigm of CD and generate hypotheses for future trials. The objective of this analysis was to determine whether baseline patient characteristics are predictive of remission and the drug durability of ustekinumab, and whether its positioning with respect to prior use of biologics has a significant effect after correcting for disease severity and phenotype at baseline using interpretable machine learning. Patients' data from SUSTAIN, a retrospective multicenter single-arm cohort study, were used. Disease phenotype, baseline laboratory data, and prior treatment characteristics were documented. Clinical remission was defined as the Harvey Bradshaw Index <= 4 and was tracked longitudinally. Drug durability was defined as the time until a patient discontinued treatment. A total of 439 participants from 60 centers were included and a total of 20 baseline covariates considered. Less exposure to previous biologics had a positive effect on remission, even after controlling for baseline disease severity using a non-linear, additive, multivariable model. Additionally, age, body mass index, and fecal calprotectin at baseline were found to be statistically significant as independent negative risk factors for both remission and drug survival, with further risk factors identified for remission

Predictors of Response to Exclusive Enteral Nutrition in Newly Diagnosed Crohn´s Disease in Children: PRESENCE Study from SEGHNP

Exclusive enteral nutrition (EEN) has been shown to be more effective than corticosteroids in achieving mucosal healing in children with Crohn´s disease (CD) without the adverse effects of these drugs. The aims of this study were to determine the efficacy of EEN in terms of inducing clinical remission in children newly diagnosed with CD, to describe the predictive factors of response to EEN and the need for treatment with biological agents during the first 12 months of the disease. We conducted an observational retrospective multicentre study that included paediatric patients newly diagnosed with CD between 2014–2016 who underwent EEN. Two hundred and twenty-two patients (140 males) from 35 paediatric centres were included, with a mean age at diagnosis of 11.6 ± 2.5 years. The median EEN duration was 8 weeks (IQR 6.6–8.5), and 184 of the patients (83%) achieved clinical remission (weighted paediatric Crohn’s Disease activity index [wPCDAI] 15 mg/L and ileal involvement tended to respond better to EEN. EEN administered for 6–8 weeks is effective for inducing clinical remission. Due to the high response rate in our series, EEN should be used as the first-line therapy in luminal paediatric Crohn’s disease regardless of the location of disease and disease activityS

Derecho, género e igualdad : cambios en las estructuras jurídicas androcéntricas. Vol I

Este libro es el resultado de trabajos seleccionados del I Congreso Internacional Derecho, Género e Igualdad, realizado en el año 2009 en la Universidad de Barcelona por el Grupo Antígona y el Grupo Dones i Drets

Mutations, Genes, and Phenotypes Related to Movement Disorders and Ataxias

26 páginas, 4 figuras, 3 tablasOur clinical series comprises 124 patients with movement disorders (MDs) and/or ataxia with cerebellar atrophy (CA), many of them showing signs of neurodegeneration with brain iron accumulation (NBIA). Ten NBIA genes are accepted, although isolated cases compatible with abnormal brain iron deposits are known. The patients were evaluated using standardised clinical assessments of ataxia and MDs. First, NBIA genes were analysed by Sanger sequencing and 59 patients achieved a diagnosis, including the detection of the founder mutation PANK2 p.T528M in Romani people. Then, we used a custom panel MovDisord and/or exome sequencing; 29 cases were solved with a great genetic heterogeneity (34 different mutations in 23 genes). Three patients presented brain iron deposits with Fe-sensitive MRI sequences and mutations in FBXO7, GLB1, and KIF1A, suggesting an NBIA-like phenotype. Eleven patients showed very early-onset ataxia and CA with cortical hyperintensities caused by mutations in ITPR1, KIF1A, SPTBN2, PLA2G6, PMPCA, and PRDX3. The novel variants were investigated by structural modelling, luciferase analysis, transcript/minigenes studies, or immunofluorescence assays. Our findings expand the phenotypes and the genetics of MDs and ataxias with early-onset CA and cortical hyperintensities and highlight that the abnormal brain iron accumulation or early cerebellar gliosis may resembling an NBIA phenotype.This work was supported by the Instituto de Salud Carlos III (ISCIII)—Subdirección General de Evaluación y Fomento de la Investigación within the framework of the National R + D+I Plan co-funded with European Regional Development Funds (ERDF) [Grants PI18/00147 and PI21/00103 to CE]; the Fundació La Marató TV3 [Grants 20143130 and 20143131 to BPD and CE]; and by the Generalitat Valenciana [Grant PROMETEO/2018/135 to CE]. Part of the equipment employed in this work was funded by Generalitat Valenciana and co-financed with ERDF (OP ERDF of Comunitat Valenciana 2014–2020). PS had an FPU-PhD fellowship funded by the Spanish Ministry of Education, Culture and Sport [FPU15/00964]. IH has a PFIS-PhD fellowship [FI19/00072]. ASM has a contract funded by the Spanish Foundation Per Amor a l’Art (FPAA)Peer reviewe